研报掘金丨长江证券：维持梅花生物“买入”评级，诉讼或影响有限，长期发展可期

Core Viewpoint - Changjiang Securities recently reported that Meihua Biological's production and operations are normal, and the company will actively respond to legal actions to protect the legitimate rights and interests of the company and its shareholders [1] Summary by Relevant Sections - Legal Proceedings - The company is prepared to take necessary legal measures in response to ongoing litigation [1] - The outcome of the lawsuit is uncertain as the case has not yet gone to trial [1]